Core Viewpoint - The health supplement industry in China is transitioning from rapid growth to structural adjustment, with Xianle Health (300791) taking significant steps, including a planned H-share listing, amidst a projected 53% to 69% decline in net profit for 2025 [1] Financial Performance - Xianle Health ranks among the top three globally and first in China in the nutrition health food solutions industry, with revenue expected to grow from 3.582 billion RMB in 2023 to 4.211 billion RMB in 2024, reflecting a 17.6% year-on-year increase [2][3] - The company reported a revenue of 3.291 billion RMB for the first nine months of 2025, showing a 7.96% increase compared to the same period in 2024, indicating a significant slowdown in growth [2] - The gross profit margin improved from 29.65% in 2023 to 30.61% in 2024, and further to 31.48% in the first nine months of 2025, suggesting effective product structure optimization and cost control [4] Profitability Challenges - Net profit saw a dramatic decline, with 2023 net profit at 240 million RMB, increasing to 282 million RMB in 2024, but plummeting to only 55.535 million RMB in the first nine months of 2025 [5] - The company experienced a significant rise in expense ratios, with sales expense ratio increasing to 8.30% and administrative expense ratio to 10.81% in the first nine months of 2025, reflecting increased market expansion costs and decreased operational efficiency [5] Strategic Moves - The decision to pursue an H-share listing is driven by the need for capital during the industry's transition, funding for global expansion, and the establishment of a diversified capital platform [6] - Xianle Health is positioned to benefit from the global nutrition health food solutions market, which is projected to grow from 29.4 billion USD in 2024 to 42.4 billion USD by 2029, at a compound annual growth rate of 7.6% [7] Market Position and Growth Potential - The industry is characterized by a highly fragmented market with a CR5 of only 10.5%, providing opportunities for consolidation by leading companies like Xianle Health [9] - The company has established a global manufacturing network with bases in China, Europe, North America, and Southeast Asia, with a significant investment in a Thai facility aimed at serving the Asia-Pacific market [9] Innovation and Adaptation - Xianle Health is adapting to new consumer channels, with over 50% of revenue coming from social e-commerce and new retail, and has seen a 60% growth in products targeting young female consumers [10] - The company is focusing on core competencies in soft capsules and gummies, which are growing faster than the industry average, establishing a competitive edge in these segments [9]

Core Viewpoint - The company has released its 2025 earnings forecast and 2026 incentive plans, indicating a significant decline in expected profits due to asset impairment provisions related to BFPC and Hubei Yibenhui investments [1] Earnings Forecast - The company anticipates a net profit attributable to shareholders of between 101 million to 151 million yuan for 2025, representing a year-on-year decline of 68.85% to 53.44% [1] - The non-recurring net profit is expected to be between 58 million to 86 million yuan, reflecting a year-on-year decrease of 82.45% to 73.77% [1] - The impairments are primarily due to the full provision of 195 million yuan for the BFPC subsidiary and a 56.54 million yuan impairment for Hubei Yibenhui, which will not significantly impact cash flow [2] Incentive Plans - The company has introduced a restricted stock incentive plan for 2026, granting 2.2025 million shares at a price of 12.21 yuan per share, covering 85 management and core technical personnel [1][3] - The revenue targets for unlocking the incentives from 2026 to 2028 are set at no less than 5.09 billion, 5.38 billion, and 5.83 billion yuan, respectively [1] - An employee stock ownership plan has been announced, with a total of up to 32.0575 million shares, covering no more than 12 core management members, with profit targets set at 380 million yuan for 2026 and 450 million yuan for 2027 [1][3] Business Strategy - The company plans to divest the non-synergistic personal care business BFPC, which will help focus on its core operations and improve profitability [2] - The company aims for stable high single-digit compound growth in revenue, with a broader incentive coverage and increased intensity [3] - The company is positioned to capture market share in the global nutrition and health food solutions industry, which is expected to grow significantly [4] Market Position - The global nutrition and health food solutions market is projected to grow from 29.4 billion USD in 2024 to 42.4 billion USD by 2029, with a compound annual growth rate of 7.6% [4] - The company ranks third globally with a market share of 2.0%, particularly strong in gummy and soft capsule segments [4] - The company is expected to benefit from trends such as market fragmentation and customer diversification, enhancing its competitive position [4] Financial Projections - The company has adjusted its profit forecasts for 2025 to 120 million yuan, 2026 to 380 million yuan, and 2027 to 460 million yuan, reflecting the impact of impairment provisions and incentive costs [6] - The price-to-earnings ratios are projected at 60, 19, and 16 times for 2025, 2026, and 2027, respectively [6] - The target price for 2027 is maintained at 32.5 yuan, with a strong buy rating [6]